Dyax is focused on identifying and developing treatments for patients who experience plasma kallikrein (bradykinin) mediated angioedema. Using our phage display technology, we developed ecallantide, a compound shown in vitro to be a high affinity, high specificity inhibitor of human plasma kallikrein. Plasma kallikrein, an enzyme found in blood, produces bradykinin, a protein that causes blood vessels to enlarge or dilate, which can cause swelling known as angioedema. Plasma kallikrein is believed to be a key component in the regulation of inflammation and contact activation pathways. Excess plasma kallikrein activity is known to play a role in HAE and may play a role in other diseases, including idiopathic angioedema.
We have three key areas of activity in our angioedema portfolio:
We developed KALBITOR (ecallantide) on our own, and since February 2010, we have been selling it in the United States for the treatment of acute attacks of HAE. Outside of the United States, we have established partnerships to obtain regulatory approval for and commercialization of KALBITOR in certain markets and we are evaluating opportunities in others. Click here for more information on KALBITOR.
Please see Important Safety Information and Full Prescribing information, including Boxed Warning and Medication Guide at www.KALBITOR.com.
We are identifying diagnostic strategies to assist in the differentiation between histamine-mediated and plasma kallikrein (bradykinin) mediated angioedema, including development of a laboratory test. Click here for more information on our diagnostic strategies.
We are developing DX-2930, a fully human monoclonal antibody inhibitor of plasma kallikrein, which could be a candidate to prophylactically treat plasma kallikrein (bradykinin) mediated angioedemas. Click here For more information on DX-2930.